SEARCH

SEARCH BY CITATION

References

  • Alcindor, T., Kimlinger, T. & Witzig, T.E. (2006) High expression of CD59 and CD55 on benign and malignant plasma cells. Leukaemia & Lymphoma, 47, 919921.
  • Bakkus, M.H., Van Riet, I., Van Camp, B. & Thielemans, K. (1994) Evidence that the clonogenic cell in multiple myeloma originates from a pre-switched but somatically mutated B cell. British Journal Haematology, 87, 6874.
  • Bataille, R., Barlogie, B., Lu, Z.Y., Rossi, J.F., Lavabre-Bertrand, T., Beck, T., Wijdenes, J., Brochier, J. & Klein, B. (1995) Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood, 86, 685691.
  • Bello, C. & Sotomayor, E.M. (2007) Monoclonal antibodies for B-cell lymphomas: rituximab and beyond. Hematology (American Society of Hematology Education Program), 233242.
  • Berenson, J.R., Vescio, R.A. & Said, J. (1998) Multiple myeloma: the cells of origin – a two-way street. Leukemia, 12, 121127.
  • Bergua, J.M., Cabrera, C., Arteta, E.G. & Prieto, J. (2007) Rituximab in CD20 positive multiple myeloma. Leukemia, (doi: 10.1038/sj.leu.2405010).
  • Billadeau, D., Ahmann, G., Greipp, P. & Van Ness, B. (1993) The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell. Journal of Experimental Medicine, 178, 10231031.
  • Boye, J., Elter, T. & Engert, A. (2003) An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Annals of Oncology, 14, 520535.
  • Braylan, R.C., Orfao, A., Borowitz, M.J. & Davis, B.H. (2001) Optimal number of reagents required to evaluate hematolymphoid neoplasias: results of an international consensus meeting. Cytometry, 46, 2327.
  • Bringhen, S., Avonto, I., Magarotto, V., Boccadoro, M. & Palumbo, A. (2006) Investigational treatments for multiple myeloma. Expert Opinion on Investigational Drugs, 15, 15651582.
  • Burton, J.D., Ely, S., Reddy, P.K., Stein, R., Gold, D.V., Cardillo, T.M. & Goldenberg, D.M. (2004) CD74 is expressed by multiple myeloma and is a promising target for therapy. Clinical Cancer Research, 10, 66066611.
  • Calame, K.L. (2001) Plasma cells: finding new light at the end of B cell development. Nature Immunology, 2, 11031108.
  • Campbell, P. & Marcus, R. (2003) Monoclonal antibody therapy for lymphoma. Blood Reviews, 17, 143152.
  • Carlo-Stella, C., Guidetti, A., Di Nicola, M., Longoni, P., Cleris, L., Lavazza, C., Milanesi, M., Milani, R., Carrabba, M., Farina, L., Formelli, F., Gianni, A.M. & Corradini, P. (2006) CD52 antigen expressed by malignant plasma cells can be targeted by alemtuzumab in vivo in NOD/SCID mice. Experimental Hematology, 34, 721727.
  • Carlo-Stella, C., Guidetti, A., Di Nicola, M., Lavazza, C., Cleris, L., Sia, D., Longoni, P., Milanesi, M., Magni, M., Nagy, Z., Corradini, P., Carbone, A., Formelli, F. & Gianni, A.M. (2007) IFN-gamma enhances the antimyeloma activity of the fully human anti-human leukocyte antigen-DR monoclonal antibody 1D09C3. Cancer Research, 67, 32693275.
  • Chatterjee, M., Chakraborty, T. & Tassone, P. (2006) Multiple myeloma: monoclonal antibodies-based immunotherapeutic strategies and targeted radiotherapy. European Journal of Cancer, 42, 16401652.
  • Chen, B.J. & Epstein, J. (1996) Circulating clonal lymphocytes in myeloma constitute a minor subpopulation of B cells. Blood, 87, 19721976.
  • Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., Reyes, F., Lederlin, P. & Gisselbrecht, C. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. New England Journal of Medicine, 346, 235242.
  • Coleman, E.J., Brooks, K.J., Smallshaw, J.E. & Vitetta, E.S. (2006) The Fc portion of UV3, an anti-CD54 monoclonal antibody, is critical for its antitumor activity in SCID mice with human multiple myeloma or lymphoma cell lines. Journal of Immunotherapy, 1997, 29.
  • Corradini, P., Boccadoro, M., Voena, C. & Pileri, A. (1993) Evidence for a bone marrow B cell transcribing malignant plasma cell VDJ joined to C mu sequence in immunoglobulin (IgG)- and IgA-secreting multiple myelomas. Journal of Experimental Medicine, 178, 10911096.
  • Cremer, F.W., Goldschmidt, H. & Moos, M. (2001) Clonotypic B cells in the peripheral blood of patients with multiple myeloma. Blood, 97, 29132914.
  • Davies, F.E., Rawstron, A.C., Pratt, G., O’Connor, S., Su’ut, L., Blythe, D., Fenton, J., Claydon, D., Child, J.A., Jack, A.S. & Morgan, G.J. (1999) FICTION-TSA analysis of the B-cell compartment in myeloma shows no significant expansion of myeloma precursor cells. British Journal Haematology, 106, 4046.
  • Davies, F.E., Rawstron, A.C., Owen, R.G. & Morgan, G.J. (2000) Controversies surrounding the clonogenic origin of multiple myeloma. British Journal Haematology, 110, 240241.
  • Davis, B.H., Holden, J.T., Bene, M.C., Borowitz, M.J., Braylan, R.C., Cornfield, D., Gorczyca, W., Lee, R., Maiese, R., Orfao, A., Wells, D., Wood, B.L. & Stetler-Stevenson, M. (2007) 2006 Bethesda International Consensus recommendations on the flow cytometric immunophenotypic analysis of hematolymphoid neoplasia: medical indications. Cytometry. Part B, Clinical Cytometry, 72(Suppl. 1), S5S13.
  • Dimopoulos, M.A., Zervas, C., Zomas, A., Kiamouris, C., Viniou, N.A., Grigoraki, V., Karkantaris, C., Mitsouli, C., Gika, D., Christakis, J. & Anagnostopoulos, N. (2002) Treatment of Waldenstrom’s macroglobulinemia with rituximab. Journal of Clinical Oncology, 20, 23272333.
  • Epstein, J. (1997) Myeloma stem cell phenotype. Implications for treatment. Hematology/Oncology Clinics of North America, 11, 4349.
  • Feugier, P., Van Hoof, A., Sebban, C., Solal-Celigny, P., Bouabdallah, R., Ferme, C., Christian, B., Lepage, E., Tilly, H., Morschhauser, F., Gaulard, P., Salles, G., Bosly, A., Gisselbrecht, C., Reyes, F. & Coiffier, B. (2005) Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. Journal of Clinical Oncology, 23, 41174126.
  • Fonseca, R., Blood, E.A., Oken, M.M., Kyle, R.A., Dewald, G.W., Bailey, R.J., Van Wier, S.A., Henderson, K.J., Hoyer, J.D., Harrington, D., Kay, N.E., Van Ness, B. & Greipp, P.R. (2002) Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients. Blood, 99, 37353741.
  • Friedberg, J.W. (2005) Unique toxicities and resistance mechanisms associated with monoclonal antibody therapy. Hematology (American Society of Hematology Education Program), 329334.
  • Garcia-Sanz, R., Orfao, A., Gonzalez, M., Tabernero, M.D., Blade, J., Moro, M.J., Fernandez-Calvo, J., Sanz, M.A., Perez-Simon, J.A., Rasillo, A. & Miguel, J.F. (1999) Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood, 93, 10321037.
  • Gasparetto, C., Horwitz, M.E., Gockerman, J.P., De Castro, C.M., Moore, J.O., Smith, C.A., Davis, P., Lassite, M., Houser, L., Chao, N.J. & Rizzieri, D. (2004) Campath-1H may have activity in the treatment of multiple myeloma. Blood, 104, 4931 (abstract).
  • Gemmel, C., Cremer, F.W., Weis, M., Witzens, M., Moldenhauer, G., Koniczek, K.H., Imbach, U., Ho, A.D., Moos, M. & Goldschmidt, H. (2002) Anti-CD20 antibody as consolidation therapy in a patient with primary plasma cell leukemia after high-dose therapy and autologous stem cell transplantation. Annals of Hematology, 81, 119123.
  • Gertz, M.A., Rue, M., Blood, E., Kaminer, L.S., Vesole, D.H. & Greipp, P.R. (2004) Multicenter phase 2 trial of rituximab for Waldenstrom macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98). Leukaemia & Lymphoma, 45, 20472055.
  • Ghobrial, I.M., Fonseca, R., Greipp, P.R., Blood, E., Rue, M., Vesole, D.H. & Gertz, M.A. (2004) Initial immunoglobulin M ‘flare’ after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study. Cancer, 101, 25932598.
  • Gorschluter, M., Ziske, C., Glasmacher, A. & Schmidt-Wolf, I.G. (2001) Current clinical and laboratory strategies to augment the efficacy of immunotherapy in multiple myeloma. Clinical Cancer Research, 7, 21952204.
  • Gozzetti, A., Fabbri, A., Lazzi, S., Bocchia, M. & Lauria, F. (2007) Reply to rituximab activity in CD20 positive multiple myeloma. Leukemia, (doi: 10.1038/sj.leu.2405011).
  • Greipp, P.T., Kapoor, P., Morice, W.G., Witzig, T.E. & Greipp, P.R. (2008) Reply to ‘rituximab in CD20 positive multiple myeloma’ by P Moreau et al. Leukemia, 22, 214215.
  • Grillo-Lopez, A.J. (2000) Rituximab: an insider’s historical perspective. Seminars in Oncology, 27, 916.
  • Grossbard, M.L., Lambert, J.M., Goldmacher, V.S., Spector, N.L., Kinsella, J., Eliseo, L., Coral, F., Taylor, J.A., Blattler, W.A., Epstein, C.L. & Nadler, L.M. (1993) Anti-B4-blocked ricin: a phase I trial of 7-day continuous infusion in patients with B-cell neoplasms. Journal of Clinical Oncology, 11, 726737.
  • Guikema, J.E., Hovenga, S., Vellenga, E. & Bos, N.A. (2004) Heterogeneity in the multiple myeloma tumor clone. Leukaemia & Lymphoma, 45, 857871.
  • Guyre, P.M., Morganelli, P.M. & Miller, R. (1983) Recombinant immune interferon increases immunoglobulin G Fc receptors on cultured human mononuclear phagocytes. Journal of Clinical Investigation, 72, 393397.
  • Himmelmann, A., Riva, A., Wilson, G.L., Lucas, B.P., Thevenin, C. & Kehrl, J.H. (1997) PU.1/Pip and basic helix loop helix zipper transcription factors interact with binding sites in the CD20 promoter to help confer lineage- and stage-specific expression of CD20 in B lymphocytes. Blood, 90, 39843995.
  • Hofer, S., Hunziker, S., Dirnhofer, S. & Ludwig, C. (2003) Rituximab effective in a patient with refractory autoimmune haemolytic anaemia and CD20-negative multiple myeloma. British Journal Haematology, 122, 690691.
  • Hsi, E., Hussein, M.A., Elson, P., Karam, M.A., Andresen, S., Srkalovic, G. & Fishleder, A. (2001) Biologic and clinical evaluation of rituxan (RT) in the management of newly diagnosed multiple myeloma (MM) patients (Pts) an update (abstract). Proceedings of the American Society of Clinical Oncology, 21, 299.
  • Hussein, M.A., Berenson, J.R., Niesvizky, R., Munshi, N.C., Harrop, K.L., McDonald, M. & Drachman, J.G. (2005) A phase I humanized anti-CD40 monoclonal antibody (SGN-40) in patients with multiple myeloma. Blood, 106, 2572 (abstract).
  • Jones, R.J., Matsui, W.H. & Smith, B.D. (2004) Cancer stem cells: are we missing the target? Journal of the National Cancer Institute, 96, 583585.
  • Katzel, J.A., Hari, P. & Vesole, D.H. (2007) Multiple myeloma: charging toward a bright future. CA: A Cancer Journal for Clinicians, 57, 301318.
  • Kawai, S., Yoshimura, Y., Iida, S., Kinoshita, Y., Koishihara, Y., Ozaki, S., Matsumoto, T., Kosaka, M. & Yamada-Okabe, H. (2006) Antitumor activity of humanized monoclonal antibody against HM1.24 antigen in human myeloma xenograft models. Oncology Reports, 15, 361367.
  • Klein, B., Wijdenes, J., Zhang, X.G., Jourdan, M., Boiron, J.M., Brochier, J., Liautard, J., Merlin, M., Clement, C., Morel-Fournier, B., Lu, Z.Y., Mannoni, P. & Bataille, R. (1991) Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood, 78, 11981204.
  • Kohler, G. & Milstein, C. (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature, 256, 495497.
  • Korte, W., Jost, C., Cogliatti, S., Hess, U. & Cerny, T. (1999) Accelerated progression of multiple myeloma during anti-CD20 (Rituximab) therapy. Annals of Oncology, 10, 12491250.
  • Kosmas, C., Stamatopoulos, K., Stavroyianni, N., Zoi, K., Belessi, C., Viniou, N., Kollia, P. & Yataganas, X. (2000) Origin and diversification of the clonogenic cell in multiple myeloma: lessons from the immunoglobulin repertoire. Leukemia, 14, 17181726.
  • Kumar, S., Kimlinger, T.K., Lust, J.A., Donovan, K. & Witzig, T.E. (2003) Expression of CD52 on plasma cells in plasma cell proliferative disorders. Blood, 102, 10751077.
  • Lalazar, G., Rund, D. & Shouval, D. (2007) Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. British Journal Haematology, 136, 699712.
  • Leo, R., Boeker, M., Peest, D., Hein, R., Bartl, R., Gessner, J.E., Selbach, J., Wacker, G. & Deicher, H. (1992) Multiparameter analyses of normal and malignant human plasma cells: CD38 + +, CD56 +, CD54 +, cIg+ is the common phenotype of myeloma cells. Annals of Hematology, 64, 132139.
  • Li, J.L., Liu, Y.R., Chang, Y., Fu, J.Y. & Chen, S.S. (2002a) Immunophenotypic characteristics of multiple myeloma cells. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 10, 226228.
  • Li, J., Luo, S.K., Xiong, W.J. & Zhou, Z.H. (2002b) Combination of thalidomide and rituximab in suppressing myeloma cells in vitro. Ai Zheng, 21, 13241327.
  • Lim, S.H., Zhang, Y., Wang, Z., Varadarajan, R., Periman, P. & Esler, W.V. (2004) Rituximab administration following autologous stem cell transplantation for multiple myeloma is associated with severe IgM deficiency. Blood, 103, 19711972.
  • Lin, P., Owens, R., Tricot, G. & Wilson, C.S. (2004a) Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. American Journal of Clinical Pathology, 121, 482488.
  • Lin, P., Mahdavy, M., Zhan, F., Zhang, H.Z., Katz, R.L. & Shaughnessy, J.D. (2004b) Expression of PAX5 in CD20-positive multiple myeloma assessed by immunohistochemistry and oligonucleotide microarray. Modern Pathology, 17, 12171222.
  • Maloney, D.G. (2007) Follicular NHL: From antibodies and vaccines to graft-versus-lymphoma effects. Hematology (American Society of Hematology Education Program), 226232.
  • Maloney, D.G., Donovan, K. & Hamblin, T.J. (1999) Antibody therapy for treatment of multiple myeloma. Seminars in Hematology, 36, 3033.
  • Mateo, G., Castellanos, M., Rasillo, A., Gutierrez, N.C., Montalban, M.A., Martin, M.L., Hernandez, J.M., Lopez-Berges, M.C., Montejano, L., Blade, J., Mateos, M.V., Sureda, A., De La Rubia, J., Diaz-Mediavilla, J., Pandiella, A., Lahuerta, J.J., Orfao, A. & San Miguel, J.F. (2005) Genetic abnormalities and patterns of antigenic expression in multiple myeloma. Clinical Cancer Research, 11, 36613667.
  • Matsuda, I., Mori, Y., Nakagawa, Y., Sawanobori, M., Uemura, N. & Suzuki, K. (2005) Close correlations between CD20 expression, a small mature plasma cell morphology and t(11; 14) in multiple myeloma. Rinsho Ketsueki, 46, 12931297.
  • Matsui, W., Huff, C.A., Wang, Q., Malehorn, M.T., Barber, J., Tanhehco, Y., Smith, B.D., Civin, C.I. & Jones, R.J. (2004) Characterization of clonogenic multiple myeloma cells. Blood, 103, 23322336.
  • McEarchern, J.A., McDonagh, C., Ho, A., Tai, Y.T., Francisco, L., Klussman, K., Morris-Tilden, C., Gordon, K., Oflazoglu, E., Kissler, K., Munshi, N., Anderson, K.C., Treon, S.P., Carter, P., Wahl, A.F., Grewal, I.S. & Law, C. (2005) A humanized anti-CD70 monoclonal antibody targets CD70-expressing multiple myeloma. Blood, 106, 1591 (abstract).
  • McEarchern, J.A., Oflazoglu, E., Francisco, L., McDonagh, C.F., Gordon, K.A., Stone, I., Klussman, K., Turcott, E., Van Rooijen, N., Carter, P., Grewal, I.S., Wahl, A.F. & Law, C.L. (2007) Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities. Blood, 109, 11851192.
  • Mitterer, M., Oduncu, F., Lanthaler, A.J., Drexler, E., Amaddii, G., Fabris, P., Emmerich, B., Coser, P. & Straka, C. (1999) The relationship between monoclonal myeloma precursor B cells in the peripheral blood stem cell harvests and the clinical response of multiple myeloma patients. British Journal Haematology, 106, 737743.
  • Moreau, P., Harousseau, J.L., Wijdenes, J., Morineau, N., Milpied, N. & Bataille, R. (2000) A combination of anti-interleukin 6 murine monoclonal antibody with dexamethasone and high-dose melphalan induces high complete response rates in advanced multiple myeloma. British Journal Haematology, 109, 661664.
  • Moreau, P., Hullin, C., Garban, F., Yakoub-Agha, I., Benboubker, L., Attal, M., Marit, G., Fuzibet, J.G., Doyen, C., Voillat, L., Berthou, C., Ketterer, N., Casassus, P., Monconduit, M., Michallet, M., Najman, A., Sotto, J.J., Bataille, R. & Harousseau, J.L. (2006) Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol. Blood, 107, 397403.
  • Moreau, P., Voillat, L., Benboukher, L., Mathiot, C., Dumontet, C., Robillard, N., Herault, O., Garnache, F., Garand, R., Varoqueaux, N., Avet-Loiseau, H., Harousseau, J.L. & Bataille, R. (2007) Rituximab in CD20 positive multiple myeloma. Leukemia, 4, 835836.
  • Musto, P., Carella, A.M. Jr, Greco, M.M., Falcone, A., Sanpaolo, G., Bodenizza, C., Cascavilla, N., Melillo, L. & Carella, A.M. (2003) Short progression-free survival in myeloma patients receiving rituximab as maintenance therapy after autologous transplantation. British Journal Haematology, 123, 746747.
  • Nagy, Z.A., Hubner, B., Lohning, C., Rauchenberger, R., Reiffert, S., Thomassen-Wolf, E., Zahn, S., Leyer, S., Schier, E.M., Zahradnik, A., Brunner, C., Lobenwein, K., Rattel, B., Stanglmaier, M., Hallek, M., Wing, M., Anderson, S., Dunn, M., Kretzschmar, T. & Tesar, M. (2002) Fully human, HLA-DR-specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells. Nature Medicine, 8, 801807.
  • Niscola, P., Del Principe, M.I., Maurillo, L., Venditti, A., Buccisano, F., Piccioni, D., Amadori, S. & Del Poeta, G. (2005) Fulminant B hepatitis in a surface antigen-negative patient with B-cell chronic lymphocytic leukaemia after rituximab therapy. Leukemia, 19, 18401841.
  • Ozaki, S., Kosaka, M., Wakatsuki, S., Abe, M., Koishihara, Y. & Matsumoto, T. (1997) Immunotherapy of multiple myeloma with a monoclonal antibody directed against a plasma cell-specific antigen, HM1.24. Blood, 90, 31793186.
  • Peacock, C.D., Wang, Q., Gesell, G.S., Corcoran-Schwartz, I.M., Jones, E., Kim, J., Devereux, W.L., Rhodes, J.T., Huff, C.A., Beachy, P.A., Watkins, D.N. & Matsui, W. (2007) Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma. Proceedings of the National Academy of Sciences of the United States of America, 104, 40484053.
  • Pettersson, M., Sundstrom, C., Nilsson, K. & Larsson, L.G. (1995) The hematopoietic transcription factor PU.1 is downregulated in human multiple myeloma cell lines. Blood, 86, 27472753.
  • Pilarski, L.M., Hipperson, G., Seeberger, K., Pruski, E., Coupland, R.W. & Belch, A.R. (2000) Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice. Blood, 95, 10561065.
  • Rajkumar, S.V. & Kyle, R.A. (2005) Multiple myeloma: diagnosis and treatment. Mayo Clinic Proceedings, 80, 13711382.
  • Rawstron, A.C., Barrans, S.L., Blythe, D., English, A., Richards, S.J., Fenton, J.A., Davies, F.E., Child, J.A., Jack, A.S. & Morgan, G.J. (2001) In multiple myeloma, only a single stage of neoplastic plasma cell differentiation can be identified by VLA-5 and CD45 expression. British Journal Haematology, 113, 794802.
  • Rawstron, A.C., Laycock-Brown, G., Hale, G., Davies, F.E., Morgan, G.J., Child, J.A., Hillmen, P. & Owen, R.G. (2006) CD52 expression patterns in myeloma and the applicability of alemtuzumab therapy. Haematologica, 91, 15771578.
  • Reff, M.E., Carner, K., Chambers, K.S., Chinn, P.C., Leonard, J.E., Raab, R., Newman, R.A., Hanna, N. & Anderson, D.R. (1994) Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood, 83, 435445.
  • Reya, T., Morrison, S.J., Clarke, M.F. & Weissman, I.L. (2001) Stem cells, cancer, and cancer stem cells. Nature, 414, 105111.
  • Riley, J.K. & Sliwkowski, M.X. (2000) CD20: a gene in search of a function. Seminars in Oncology, 27, 1724.
  • Robillard, N., Avet-Loiseau, H., Garand, R., Moreau, P., Pineau, D., Rapp, M.J., Harousseau, J.L. & Bataille, R. (2003) CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma. Blood, 102, 10701071.
  • Rossi, J.F., Fegueux, N., Lu, Z.Y., Legouffe, E., Exbrayat, C., Bozonnat, M.C., Navarro, R., Lopez, E., Quittet, P., Daures, J.P., Rouille, V., Kanouni, T., Widjenes, J. & Klein, B. (2005) Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140 mg/m2 of melphalan in multiple myeloma: results of a pilot study including biological aspects. Bone Marrow Transplantation, 36, 771779.
  • Rottenburger, C., Kiel, K., Bosing, T., Cremer, F.W., Moldenhauer, G., Ho, A.D., Goldschmidt, H. & Moos, M. (1999) Clonotypic CD20 +  and CD19 +  B cells in peripheral blood of patients with multiple myeloma post high-dose therapy and peripheral blood stem cell transplantation. British Journal Haematology, 106, 545552.
  • Ruffini, P.A. & Kwak, L.W. (2001) Immunotherapy of multiple myeloma. Seminars in Hematology, 38, 260267.
  • San Miguel, J.F., Gonzalez, M., Gascon, A., Moro, M.J., Hernandez, J.M., Ortega, F., Jimenez, R., Guerras, L., Romero, M., Casanova, F., Sanz, M.A., Portero, J.A. & Orfao, A. (1991) Immunophenotypic heterogeneity of multiple myeloma: influence on the biology and clinical course of the disease. Castellano-Leones (Spain) Cooperative Group for the Study of Monoclonal Gammopathies. British Journal Haematology, 77, 185190.
  • Sekimoto, E., Ozaki, S., Ohshima, T., Shibata, H., Hashimoto, T., Abe, M., Kimura, N., Hattori, K., Kawai, S., Kinoshita, Y., Yamada-Okabe, H., Tsuchiya, M. & Matsumoto, T. (2007) A single-chain Fv diabody against human leukocyte antigen-A molecules specifically induces myeloma cell death in the bone marrow environment. Cancer Research, 67, 11841192.
  • Shapiro-Shelef, M. & Calame, K. (2004) Plasma cell differentiation and multiple myeloma. Current Opinion in Immunology, 16, 226234.
  • Sharkey, R.M. & Goldenberg, D.M. (2006) Targeted therapy of cancer: new prospects for antibodies and immunoconjugates. CA: A Cancer Journal for Clinicians, 56, 226243.
  • Sivaraman, S., Venugopal, P., Ranganathan, R., Deshpande, C.G., Huang, X., Jajeh, A., Gregory, S.A., O’Brien, T. & Preisler, H.D. (2000) Effect of interferon-alpha on CD20 antigen expression of B-cell chronic lymphocytic leukemia. Cytokines, Cellular & Molecular Therapy, 6, 8187.
  • Smallshaw, J.E., Coleman, E., Spiridon, C. & Vitetta, E.S. (2004) The generation and anti-myeloma activity of a chimeric anti-CD54 antibody, cUV3. Journal of Immunotherapy, 1997, 27.
  • Smith, M.R. (2003) Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene, 22, 73597368.
  • Stein, R., Qu, Z., Cardillo, T.M., Chen, S., Rosario, A., Horak, I.D., Hansen, H.J. & Goldenberg, D.M. (2004) Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies. Blood, 104, 37053711.
  • Stein, R., Mattes, M.J., Cardillo, T.M., Hansen, H.J., Chang, C.H., Burton, J., Govindan, S. & Goldenberg, D.M. (2007) CD74: a new candidate target for the immunotherapy of B-cell neoplasms. Clinical Cancer Research, 13, 5556s5563s.
  • Stevenson, G.T. (2006) CD38 as a therapeutic target. Molecular Medicine, 12, 345346.
  • Tai, Y.T., Li, X., Tong, X., Santos, D., Otsuki, T., Catley, L., Tournilhac, O., Podar, K., Hideshima, T., Schlossman, R., Richardson, P., Munshi, N.C., Luqman, M. & Anderson, K.C. (2005) Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma. Cancer Research, 65, 58985906.
  • Tai, Y.T., Dillon, M., Song, W., Leiba, M., Li, X.F., Burger, P., Lee, A.I., Podar, K., Hideshima, T., Rice, A.G., Van Abbema, A., Jesaitis, L., Caras, I., Law, D., Weler, E., Xie, W., Richardson, P., Munshi, N.C., Mathiot, C., Avet-Loiseau, H., Afar, D.E. & Anderson, K.C. (2007) Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood, (doi: 10.1182/blood-2007-08-107292).
  • Tassone, P., Gozzini, A., Goldmacher, V., Shammas, M.A., Whiteman, K.R., Carrasco, D.R., Li, C., Allam, C.K., Venuta, S., Anderson, K.C. & Munshi, N.C. (2004a) In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2’-deacetyl-N2’-(3-mercapto-1-oxopropyl)-maytansine against CD56 +  multiple myeloma cells. Cancer Research, 64, 46294636.
  • Tassone, P., Goldmacher, V.S., Neri, P., Gozzini, A., Shammas, M.A., Whiteman, K.R., Hylander-Gans, L.L., Carrasco, D.R., Hideshima, T., Shringarpure, R., Shi, J., Allam, C.K., Wijdenes, J., Venuta, S., Munshi, N.C. & Anderson, K.C. (2004b) Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138 +  multiple myeloma cells. Blood, 104, 36883696.
  • Tedder, T.F. & Engel, P. (1994) CD20: a regulator of cell-cycle progression of B lymphocytes. Immunology Today, 15, 450454.
  • Treon, S.P., Shima, Y., Preffer, F.I., Doss, D.S., Ellman, L., Schlossman, R.L., Grossbard, M.L., Belch, A.R., Pilarski, L.M. & Anderson, K.C. (1999) Treatment of plasma cell dyscrasias by antibody-mediated immunotherapy. Seminars in Oncology, 26, 97106.
  • Treon, S.P., Mitsiades, C., Mitsiades, N., Young, G., Doss, D., Schlossman, R. & Anderson, K.C. (2001) Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies. Journal of Immunotherapy, 24, 263271.
  • Treon, S.P., Pilarski, L.M., Belch, A.R., Kelliher, A., Preffer, F.I., Shima, Y., Mitsiades, C.S., Mitsiades, N.S., Szczepek, A.J., Ellman, L., Harmon, D., Grossbard, M.L. & Anderson, K.C. (2002) CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications. Journal of Immunotherapy, 25, 7281.
  • Treon, S.P., Branagan, A.R., Hunter, Z., Santos, D., Tournhilac, O. & Anderson, K.C. (2004) Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom’s macroglobulinemia. Annals of Oncology, 15, 14811483.
  • Trikha, M., Corringham, R., Klein, B. & Rossi, J.F. (2003) Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clinical Cancer Research, 9, 46534665.
  • Weiner, L.M., Steplewski, Z., Koprowski, H., Litwin, S. & Comis, R.L. (1988) Divergent dose-related effects of gamma-interferon therapy on in vitro antibody-dependent cellular and nonspecific cytotoxicity by human peripheral blood monocytes. Cancer Research, 48, 10421046.
  • Weng, W.K. & Levy, R. (2001) Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma. Blood, 98, 13521357.
  • Westhoff, T.H., Jochimsen, F., Schmittel, A., Stoffler-Meilicke, M., Schafer, J.H., Zidek, W., Gerlich, W.H. & Thiel, E. (2003) Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood, 102, 1930.
  • Witzig, T.E. (2006) Radioimmunotherapy for B-cell non-Hodgkin lymphoma. Best Practice & Research. Clinical Haematology, 19, 655668.
  • Yaccoby, S. (2005) The phenotypic plasticity of myeloma plasma cells as expressed by dedifferentiation into an immature, resilient, and apoptosis-resistant phenotype. Clinical Cancer Research, 11, 75997606.
  • Yaccoby, S. & Epstein, J. (1999) The proliferative potential of myeloma plasma cells manifest in the SCID-hu host. Blood, 94, 35763582.
  • Yang, J., Qian, J., Wezeman, M., Wang, S., Lin, P., Wang, M., Yaccoby, S., Kwak, L.W., Barlogie, B. & Yi, Q. (2006) Targeting beta2-microglobulin for induction of tumor apoptosis in human hematological malignancies. Cancer Cell, 10, 295307.
  • Yoshio-Hoshino, N., Adachi, Y., Aoki, C., Pereboev, A., Curiel, D.T. & Nishimoto, N. (2007) Establishment of a new interleukin-6 (IL-6) receptor inhibitor applicable to the gene therapy for IL-6-dependent tumor. Cancer Research, 67, 871875.
  • Van Zaanen, H.C., Lokhorst, H.M., Aarden, L.A., Rensink, H.J., Warnaar, S.O., Van Der Lelie, J. & Van Oers, M.H. (1998) Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study. British Journal Haematology, 102, 783790.
  • Zhan, F., Hardin, J., Kordsmeier, B., Bumm, K., Zheng, M., Tian, E., Sanderson, R., Yang, Y., Wilson, C., Zangari, M., Anaissie, E., Morris, C., Muwalla, F., Van Rhee, F., Fassas, A., Crowley, J., Tricot, G., Barlogie, B. & Shaughnessy, J. Jr (2002) Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood, 99, 17451757.
  • Zhan, F., Huang, Y., Colla, S., Stewart, J.P., Hanamura, I., Gupta, S., Epstein, J., Yaccoby, S., Sawyer, J., Burington, B., Anaissie, E., Hollmig, K., Pineda-Roman, M., Tricot, G., Van Rhee, F., Walker, R., Zangari, M., Crowley, J., Barlogie, B. & Shaughnessy, J.D. Jr (2006) The molecular classification of multiple myeloma. Blood, 108, 20202028.
  • Zojer, N., Kirchbacher, K., Vesely, M., Hubl, W. & Ludwig, H. (2006) Rituximab treatment provides no clinical benefit in patients with pretreated advanced multiple myeloma. Leukaemia & Lymphoma, 47, 11031109.